Light-responsive nanomedicine for cancer immunotherapy.
10.1016/j.apsb.2023.05.016
- Author:
Weirong KANG
1
;
Yuwei LIU
1
;
Weiping WANG
1
Author Information
1. State Key Laboratory of Pharmaceutical Biotechnology, the University of Hong Kong, Hong Kong, China.
- Publication Type:Review
- Keywords:
Cancer therapy;
Immunotherapy;
Light-responsive nanoparticles;
Light-triggered drug release;
Nanomedicine;
Photodynamic therapy;
Photopharmacology;
Photothermal therapy
- From:
Acta Pharmaceutica Sinica B
2023;13(6):2346-2368
- CountryChina
- Language:English
-
Abstract:
Immunotherapy emerged as a paradigm shift in cancer treatments, which can effectively inhibit cancer progression by activating the immune system. Remarkable clinical outcomes have been achieved through recent advances in cancer immunotherapy, including checkpoint blockades, adoptive cellular therapy, cancer vaccine, and tumor microenvironment modulation. However, extending the application of immunotherapy in cancer patients has been limited by the low response rate and side effects such as autoimmune toxicities. With great progress being made in nanotechnology, nanomedicine has been exploited to overcome biological barriers for drug delivery. Given the spatiotemporal control, light-responsive nanomedicine is of great interest in designing precise modality for cancer immunotherapy. Herein, we summarized current research utilizing light-responsive nanoplatforms to enhance checkpoint blockade immunotherapy, facilitate targeted delivery of cancer vaccines, activate immune cell functions, and modulate tumor microenvironment. The clinical translation potential of those designs is highlighted and challenges for the next breakthrough in cancer immunotherapy are discussed.
